Incyte’s Q2 earnings drop Tuesday—first in biotech to report, setting the sector’s tone. Last quarter, they beat revenue and EPS estimates, though missed full-year guidance. This time, analysts expect another strong 23.7% YoY revenue jump—up from 16.5% last year—and they’re sticking to their forecasts, signaling confidence. With investors holding steady and Incyte’s stock up a couple percent, the biopharma giant’s momentum looks intact. Watch for another beat—or a surprise.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
